Type 2 diabetes: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• GLP-1 63
• SGLT2 40
• PPAR 0
• AMPK 2
• DPP-4 7
• PI3K 0
• AKT 0
• GIP 4
• mTOR 0
• NRF2 0
• NLRP3 3
• SIRT1 1
• STAT3 0
• TP53 1
• TNF 0
• MAPK 0
• PCSK9 1
• VEGF 2
• JNK 0
• TLR4 0
• FTO 0
• IL-6 2
• ERK 0
• HIF-1 0
• JAK 0
• HMGB1 0
• APOE 0
• BDNF 0
• IL-1 1
• STING 0
• CTNNB1 0
• GPX4 0
• PTEN 0
• IL-17 1
• STK11 0
• MMP-9 1
• BCL-2 0
• COX-2 0
• MEK 0
• PINK1 0
• CD40 0
• EGFR 0
• PD-1 0
• RANKL 0
• YAP 0
• ATM 0
• FGFR 0
• MET 1
• PD-L1 0
• SNCA 0
• CCR5 0
• CDKN2A 0
• CXCR4 0
• IGF1R 0
• MAPT 0
• METTL3 0
• PNPLA3 0
• ABL1 0
• BACE1 0
• CD38 0

EU-13 is a filter, not a ranking: it only narrows the list.

19 of 19+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

  NCT04906213· Duke University· Updated 27 Feb 2026

  “The study closed per PI decision due to completion of the biopsy substudy and slow accrual”Registry text, quoted unchanged. Source

• Terminated

  Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

  NCT05139914· Boston University· Updated 11 Feb 2026

  “The study was halted early because of the inability to enroll participants.”Registry text, quoted unchanged. Source

• Withdrawn

  Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin

  NCT07057479· Eurofarma Laboratorios S.A.· Updated 18 Dec 2025

  “Strategic change in development priorities”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

  NCT06534411· Novo Nordisk A/S· Source

• CGM Use in Adults With Type 2 Diabetes on Basal Insulin

  NCT05944432· Abbott Diabetes Care· Source

• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

  NCT06109311· Eli Lilly and Company· Source

• Cranberry Proanthocyanidins and Lactobacilli for Recurrent UTI Prevention in Type 2 Diabetes

  NCT07832409· National Institute of Endocrinology, Georgia· Source

• Improving Coronary Vascular Health in Women

  NCT06843902· Massachusetts General Hospital· Source

• QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

  NCT07775846· Huijie Zhang· Source

• LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

  NCT05313529· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

  NCT06297603· Eli Lilly and Company· Source

• SGLTi, Hepatic Glucose Production and Ketogenesis

  NCT05960656· The University of Texas Health Science Center at San Antonio· Source

• SGLT2i, Pioglitazone, and Ketone Production in T2D

  NCT07053319· The University of Texas Health Science Center at San Antonio· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 25
• Organoids 3
• Mendelian Randomization Analysis 228
• CRISPR-Cas Systems 5
• Gene Expression Profiling 112
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 8
• Exome Sequencing 12
• Proteomics 148
• Metabolomics 202
• Mass Spectrometry 42
• Flow Cytometry 19
• Immunohistochemistry 50
• Xenograft Model Antitumor Assays 34
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 185
• Machine Learning 194
• Deep Learning 32
• Cohort Studies 1107
• Genome-Wide Association Study 313

• Serum Metabolic Differences Across Glucose Metabolic States Using Untargeted UPLC-HRMS Metabolomics.

  J Proteome Res, Nov 2026

• Machine learning-based identification of depression in older patients with type 2 diabetes mellitus: A multicenter retrospective study.

  Sci Prog, Nov 2026

• Developing Machine Learning-Based Prognostic Models for Nonmelanoma Skin Cancer Patients With Comorbid Diabetes: A Retrospective Cohort Study.

  Cancer Med, Nov 2026

• Identification of ageing-related genes in prostate cancer with type 2 Diabetes using machine learning: a multi-omics study focusing on SOX4, PRNP, and FOXO4.

  Artif Cells Nanomed Biotechnol, Oct 2026

• Dissecting polycystic metabolic ovarian syndrome heterogeneity (PMOS): multi-omics, AI subtyping, and precision management.

  Mol Biol Rep, Oct 2026

• [Construction of predictive models for type 2 diabetic retinopathy based on the principle of differentiation of syndrome elements].

  Nan Fang Yi Ke Da Xue Xue Bao, Oct 2026

• Machine learning predictors of cardiovascular autonomic neuropathy in type 2 diabetes: insights from a prospectively collected single-center registry.

  Front Endocrinol (Lausanne), Oct 2026

• Risk prediction models for macrovascular complications in type 2 diabetes mellitus: from traditional risk scores to multimodal intelligent prediction.

  Front Endocrinol (Lausanne), Oct 2026

• Integrative Bioinformatics Analysis Incorporating Artificial Intelligence and Machine Learning Identifies Putative Pathogenic HNF1B Missense Variants Associated with HNF1B-MODY.

  Int J Mol Sci, Oct 2026

• A machine learning-driven and explainable prediction model for in-hospital mortality in patients with diabetes mellitus and congestive heart failure: integrating XGBoost and SHAP approaches.

  Front Public Health, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.